157 related articles for article (PubMed ID: 20393025)
1. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Dudek AZ; Yee RT; Manivel JC; Isaksson R; Yee HO
Anticancer Res; 2010 Mar; 30(3):987-92. PubMed ID: 20393025
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
3. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
4. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
[TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Shuch B; Li Z; Belldegrun AS
BJU Int; 2008 Jun; 101 Suppl 4():25-30. PubMed ID: 18430119
[No Abstract] [Full Text] [Related]
6. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Jensen HK; Nordsmark M; Donskov F; Marcussen N; von der Maase H
BJU Int; 2008 Jun; 101 Suppl 4():41-4. PubMed ID: 18430123
[No Abstract] [Full Text] [Related]
7. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
[TBL] [Abstract][Full Text] [Related]
10. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
[TBL] [Abstract][Full Text] [Related]
12. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
[TBL] [Abstract][Full Text] [Related]
13. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
14. [Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression].
Rubio-Briones J; Calatrava A; Fernández-Serra A; Ramos Ruiz R; Iborra I; García-Casado Z; Rubio L; Trassierra M; Collado A; Casanova J; Gómez-Ferrer A; Solsona E; López-Guerrero JA
Actas Urol Esp; 2011 Feb; 35(2):80-6. PubMed ID: 21256634
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS
J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876
[TBL] [Abstract][Full Text] [Related]
16. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Rasmussen S; Donskov F; Pedersen JW; Wandall HH; Buus S; Harndahl M; Braendstrup P; Claesson MH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):487-96. PubMed ID: 23802595
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Büscheck F; Fraune C; Simon R; Kluth M; Hube-Magg C; Möller-Koop C; Shadanpour N; Bannenberg C; Eichelberg C; Höflmayer D; Clauditz T; Wittmer C; Wilczak W; Sauter G; Fisch M; Rink M; Eichenauer T
Urol Oncol; 2018 Dec; 36(12):531.e19-531.e25. PubMed ID: 30322727
[TBL] [Abstract][Full Text] [Related]
18. [Comment to "Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression"].
Salinas AS
Actas Urol Esp; 2011 Feb; 35(2):87-8. PubMed ID: 21288602
[No Abstract] [Full Text] [Related]
19. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
[TBL] [Abstract][Full Text] [Related]
20. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
J Urol; 2008 Aug; 180(2):510-3; discussion 513-4. PubMed ID: 18550116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
